PMID- 25480466
OWN - NLM
STAT- MEDLINE
DCOM- 20150914
LR  - 20221207
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 14
IP  - 2
DP  - 2015 Feb
TI  - Do antipsychotics increase diabetes risk in children and adolescents?
PG  - 219-41
LID - 10.1517/14740338.2015.979150 [doi]
AB  - INTRODUCTION: Glucose dysregulation and type 2 diabetes mellitus (T2DM) are 
      feared antipsychotic drug adverse effects. Despite increasing utilization, data 
      about antipsychotic risk of T2DM in youth are scarce. AREAS COVERED: We conducted 
      a systematic PubMed/MEDLINE search until 15 May 2014 focusing on studies with >/= 
      20 youths aged </= 24 years, reporting quantitative data on: i) change in fasting 
      glucose, hemoglobin A1c, insulin or insulin resistance after antipsychotic 
      initiation (studies = 19, n = 2123,age = 13.3 years, follow up = 28.8 weeks); or 
      ii) prevalence (studies = 4) or incidence (studies = 8, follow up = 1.57 years) 
      of T2DM in antipsychotic-exposed youth (studies = 10, n = 65,486, age = 14.2 
      years) versus healthy controls (studies = 4, n = 246,828), psychiatric controls 
      (studies = 5, n = 61,784) or without control groups (studies = 2). EXPERT 
      OPINION: Antipsychotics are associated with early adverse changes in glucose 
      metabolism that are greater with all analyzable antipsychotics compared to 
      controls, being highest with olanzapine, followed by quetiapine, aripiprazole and 
      risperidone; but data were scarce. Although T2DM is fortunately rare in 
      antipsychotic-treated youth, its prevalence (odds ratio [OR] = 8.176, 95% CI = 
      7.139 - 9.362) and incidence (OR = 1.450, 95% CI = 1.101 - 1.911, p = 0.006) were 
      higher than in healthy controls. Similarly, T2DM prevalence (OR = 3.475, 95% CI = 
      3.019 - 4.001, p < 0.0001) and incidence (OR = 5.376, 95% CI = 4.004 - 7.233, p < 
      0.0001, excluding one outlying study) were higher than in psychiatric controls. 
      Antipsychotics should only be used after lower-risk interventions failed, and 
      inappropriately low clinical metabolic monitoring must be remedied.
FAU - Galling, Britta
AU  - Galling B
AD  - Zucker Hillside Hospital, Psychiatry Research , 75-59 263rd Street, Glen Oaks, NY 
      11001 , USA.
FAU - Correll, Christoph U
AU  - Correll CU
LA  - eng
GR  - P30MH090590/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20141205
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Insulin)
RN  - 0 (hemoglobin A1c protein, human)
SB  - IM
MH  - Adolescent
MH  - Age Factors
MH  - Antipsychotic Agents/*adverse effects
MH  - Blood Glucose/drug effects
MH  - Child
MH  - Diabetes Mellitus, Type 2/*chemically induced/*epidemiology
MH  - Glycated Hemoglobin/drug effects
MH  - Humans
MH  - Insulin/blood
MH  - Insulin Resistance
MH  - Risk Factors
OTO - NOTNLM
OT  - adolescents
OT  - antipsychotics
OT  - children
OT  - diabetes
OT  - glucose
OT  - healthy controls
OT  - hemoglobin A1c
OT  - incidence
OT  - insulin
OT  - psychiatric controls
EDAT- 2014/12/07 06:00
MHDA- 2015/09/15 06:00
CRDT- 2014/12/07 06:00
PHST- 2014/12/07 06:00 [entrez]
PHST- 2014/12/07 06:00 [pubmed]
PHST- 2015/09/15 06:00 [medline]
AID - 10.1517/14740338.2015.979150 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2015 Feb;14(2):219-41. doi: 10.1517/14740338.2015.979150. 
      Epub 2014 Dec 5.